Hims & Hers Stock Surges As It Collaborates With Novo Nordisk To Sell Weight Loss Drug Wegovy On Its Platform

Novo Nordisk A/S NVO and Hims & Hers Health, Inc. HIMS announced a long-term collaboration on Tuesday.

In March, Novo Nordisk introduced NovoCare Pharmacy, a direct-to-patient delivery service to improve access to Wegovy (semaglutide) for cash-paying patients.

Americans can now access NovoCare Pharmacy directly through the Hims & Hers platform. A bundled offering of all dose strengths of Wegovy and a Hims & Hers membership, which includes access to 24/7 care, ongoing clinical support, and nutrition guidance.

In March, Novo Nordisk announced updates to the Wegovy savings program, allowing all eligible cash-paying patients to access Wegovy (semaglutide) injections of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg at their local pharmacy for a reduced cost of $499 per month.

Previously, the $499-per-month offer for Wegovy was only available via the recently launched NovoCare Pharmacy.

Also Read: Novo Nordisk Wins Legal Battle To Curb Unsafe Knockoff Versions Of Ozempic, Wegovy

On Tuesday, the company said that at a single, unified price starting at $599 per month, individuals may be prescribed Wegovy. The offering is available this week on the Hims & Hers platform.

The companies are also developing a roadmap that combines Novo Nordisk’s treatments with Hims & Hers’ ability to scale access to quality care, aiming to improve long-term outcomes for more people.

This new offering builds on Hims & Hers’ existing suite of weight loss solutions and provides self-pay patients with access to all dose strengths of Wegovy in a high-quality pen.

The platform will continue to offer access to other medications, oral kits, protein, nutrition kits, and clinically-backed care plans.

Earlier in April, Hims & Hers Health said it would offer Eli Lilly And Co's LLY Zepbound through its Telehealth platform.

In a blog post, Hims & Hers announced that it's expanding access to personalized weight loss care.

Hims & Hers said its GLP-1 offering generated over $225 million in revenue in 2024.

Price Action: HIMS stock is up 35.5% at $38.60 during the premarket session at the last check Tuesday.

Read Next: